 |
|
Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We appreciate the many thoughtful points made by Tandon and Nasrallah, especially since we anticipated most of their points and devoted many pages of text and additional meta-analyses in the Web appendix of our article (http://www.psych.uic.edu/faculty/davis/Meta_analysis.pdf). Because of journal space limitations, which preclude lengthy technical detail, we followed the Cochrane collaboration practice of publishing extensive Web articles contemporaneously with our ARCHIVES article on our Web site shortly after the journal reached us.
Point 1: We stated in our Web supplement (Web section 2, "Study Selection") the rational for including remoxipride (its low incidence of extrapyramidal effects). Most importantly, we also conducted sensitivity analyses without remoxipride (Web Table 8) and found that the dose of comparator still failed to alter the effect and that the interaction between drug group and dose of comparator was very nonsignificant (Q2 = 1.97; P = .37). The result was essentially equivalent to . . . [Full Text of this Article]
AUTHOR INFORMATION
John M. Davis, MD;
Nancy Chen, MS;
Ira D. Glick, MD
RELATED LETTER
Subjecting Meta-analyses to Closer Scrutiny: Little Support for Differential Efficacy Among Second-Generation Antipsychotics at Equivalent Doses
Rajiv Tandon and Henry A. Nasrallah
Arch Gen Psychiatry. 2006;63(8):935-937.
EXTRACT
| FULL TEXT
RELATED ARTICLE
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
John M. Davis, Nancy Chen, and Ira D. Glick
Arch Gen Psychiatry. 2003;60(6):553-564.
ABSTRACT
| FULL TEXT
|
